CN108720018A - 一种含姜黄素的肝脏保健组合物及其方法和应用 - Google Patents

一种含姜黄素的肝脏保健组合物及其方法和应用 Download PDF

Info

Publication number
CN108720018A
CN108720018A CN201810678769.7A CN201810678769A CN108720018A CN 108720018 A CN108720018 A CN 108720018A CN 201810678769 A CN201810678769 A CN 201810678769A CN 108720018 A CN108720018 A CN 108720018A
Authority
CN
China
Prior art keywords
vitamin
parts
liver
health care
care composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201810678769.7A
Other languages
English (en)
Inventor
尹恒
陈玮
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
China Technology Co Ltd (dalian) Biotechnology Co Ltd
Original Assignee
China Technology Co Ltd (dalian) Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by China Technology Co Ltd (dalian) Biotechnology Co Ltd filed Critical China Technology Co Ltd (dalian) Biotechnology Co Ltd
Priority to CN201810678769.7A priority Critical patent/CN108720018A/zh
Publication of CN108720018A publication Critical patent/CN108720018A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/67—Piperaceae (Pepper family), e.g. Jamaican pepper or kava
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

本发明涉及一种含姜黄素的肝脏保健组合物及其应用，活性成分由姜黄素，壳寡糖，黑胡椒，维生素B1，维生素B2，维生素B3，维生素B6，维生素C，维生素E，肌醇原料组成，该组合物具有解酒保肝作用。本发明组合物具有成分明确，以多种不同的药效物质组成，利用不同的要求物质作用原理和靶点发挥解酒保肝作用，具有服用剂量小，药食同源的特点，是一种安全有效的解酒保肝食品；实验证明，本发明组合物较单一姜黄素、壳寡糖、维生素具有更强的解酒保肝活性。体现了复方组合物协同作用的特点，可用于制备具有解酒保肝作用的药品、保健食品。

Description

一种含姜黄素的肝脏保健组合物及其方法和应用
技术领域
本发明涉及食品保健领域，具体涉及一种解酒保肝的姜黄素组合 物。
背景技术
中国具有悠久的饮酒文化，酒渗透于整个中华五千年的文明史中， 在中国人生活、工作中都占有重要的位置。当前，随着生活水准日益 提高，各种酒类的需求量随之增加，同时嗜酒者的比例亦呈上升趋势， 由此造成的酒精性肝病也随之逐年增多，威胁着现代人的健康乃至生 命。“如何既能开怀畅饮，又能解酒护肝，为自己的健康保驾护航？” 这是很多人追求的目标。利用天然产物进行解酒保肝是实现此目标的 重要途径之一。
在具有饮酒传统的东亚其他国家，姜黄素已经被有效应用于解酒 产品的开发。姜黄素[curcumin,1,7-二(4-羟基-5-甲氧基)苯基-1,6-庚 二烯3,5-二酮]是从姜科植物姜黄中提取的多酚类物质，也是姜黄发挥 药理作用最重要的活性成分，其化学结构见式1。大量科学研究表明， 姜黄素除外具有抗氧化、抗炎多、抗病毒、抗肿瘤等种多种生理活性， 还能够有效降低乙醇诱导的肝细胞氧化损伤，具有解酒保肝的显著效 果。
式1姜黄素的化学结构
壳寡糖(Chitooligosaccharides，COS)是指2-10个氨基葡萄糖单位 组成的低分子量水溶性寡糖，它是由壳聚糖经酶降解或化学降解制成 的水溶性低分子量的寡糖，其化学结构见式2。研究发现，壳寡糖除具 有调节免疫、抗肿瘤、抗氧化、降血糖降血脂等活性外，还具有强化 乙醇脱氢酶、乙醛脱氢酶活性的作用，从而将饮酒者肝内的乙醇氧化 得到乙醛，并进一步将乙醛氧化成CO2与H2O，缓解乙醇对肝脏的损伤， 起到护肝作用。
式2壳寡糖的化学结构式(n≤8)
发明内容
本发明的目的在于提供一种解酒保肝的姜黄素组合物，其不仅可 以改善大量饮酒后酒精蓄积引起的肝损伤，还可以明显缓解酒后口感 舌燥的症状，具有良好的预防和治疗效果。
为实现上述目的，本发明一方面提供如下技术方案：一种肝脏保健 组合物，活性成分由姜黄素，壳寡糖，黑胡椒，维生素B1，维生素B2，维 生素B3，维生素B6，维生素C，维生素E，肌醇原料组成。
优选地，肝脏保健组合物由下述重量份的原料组成：姜黄素10-200份， 壳寡糖10-300份，黑胡椒5-50份，维生素B1 1-10份，维生素B2 1-10份， 维生素B3 1-10份，维生素B61-10份，维生素C 1-20份，维生素E 1-50 份，肌醇1-20份。
优选地，所述姜黄素的来源包括姜黄。
优选地，所述壳寡糖经酶法制备，聚合度范围2-20。
优选地，所述组合物与其他辅料混合，剂型包括软胶囊剂、硬胶囊、 片剂、颗粒剂、口服剂、饮料、果冻、糖果或软糖。
本发明另一方面，提供上述肝脏保健组合物的制备方法，将所述原料 按照比例进行物理混合处理，即得到所述肝脏保健组合物。
本发明再一方面提供上述肝脏保健组合物的应用，用于保健食品。
优选地，所述保健食品包括功能性食品。
姜黄素与壳寡糖均是具有解酒护肝功能的天然产物，但护肝机理 不尽相同，本发明提供的肝脏保健组合物含有姜黄素与壳寡糖，两者 共同存在时可以体现协同护肝作用，从而提高护肝效果；且两者均具 有其他保健活性因此，以姜黄素与壳寡糖为主要有效成分，开发新型 有效的解酒护肝产品，市场前景非常广阔。
具体实施方式
为了使本发明所述的内容更加便于理解，下面结合具体实施方式 对本发明所述的技术方案进一步的说明，但是本发明不限于此。
实施例1
含姜黄素的肝脏保健组合物，按重量百分比，包括如下组分：姜 黄素20份，壳寡糖(DP2-8)40份，黑胡椒3份，维生素B11份，维 生素B2 2份，维生素B3 2份，维生素B6 1份，维生素C 5份，维生 素E 4份，肌醇1份。
实施例2
含姜黄素的肝脏保健组合物，按重量百分比，包括如下组分：姜 黄素25份，壳寡糖(DP2-8)40份，黑胡椒5份，维生素B10.5份， 维生素B2 1份，维生素B3 1份，维生素B6 1份，维生素C 5份，维 生素E 4份，肌醇1份。
实施例3
含姜黄素的肝脏保健组合物，按重量百分比，包括如下组分：姜 黄素30份，壳寡糖(DP2-8)40份，黑胡椒5份，维生素B11份，维 生素B2 2份，维生素B3 2份，维生素B6 1份，维生素C 5份，维生 素E 4份，肌醇1份。
实施例4
含姜黄素的肝脏保健组合物，按重量百分比，包括如下组分：姜 黄素35份，壳寡糖(DP2-8)40份，黑胡椒5份，维生素B11份，维 生素B2 2份，维生素B3 2份，维生素B6 1份，维生素C 5份，维生 素E 4份，肌醇1份。
实施例5：
含姜黄素的肝脏保健组合物，按重量百分比，包括如下组分：姜 黄素40份，壳寡糖(DP2-8)40份，黑胡椒5份，维生素B12份，维 生素B2 2份，维生素B3 2份，维生素B62份，维生素C 5份，维生 素E 4份，肌醇1份。
为了证实本发明组合物的效果，采用实施例1-5的配比通过常规工 艺，即物理混合，制得含姜黄素的肝脏保健组合物，分别命名为J1、 J2、J3、J4和J5，所得剂型为粉剂进行了动物实验，具体如下。
选择SPF级SD大鼠，雄性，体重180-220g，标准环境适应性饲养1 周，给予正常饮食。将每批动物按体重随机分为9组，包括正常对照组、 模型对照组、单药组和试验组(表1)，每组8只。各组每日灌胃前禁食6h， 除正常组等量以生理盐水灌胃外，其余各组均以乙醇灌胃，5g/kg，连 续5d(1次/d)，单药各组、试验各组在乙醇灌胃1h后再按表1给予不同成分灌胃，200mg/kg，在末次乙醇灌胃并禁食6h后将全部大鼠麻醉并处 死，腹主动脉取血测定大鼠血清谷丙转氨酶(ALT)、谷草转氨酶(AST)、 总胆固醇(TC)、甘油三酯(TG)水平。取肝右叶约1g肝组织液氮下保存， 并制10％肝匀浆测定SOD，GSH-PX活性，MDA含量。采用SPSS11.5 统计软件处理，试验数据用x±s表示，计量资料采用单因素方差分析， 两组间比较采用LSD方法检验。等级资料差异性测定采用秩和检验进 行统计学处理。
表1设置试验组
对酒精性肝损伤大鼠血清ALT、AST、TC、TG水平的影响结果见表2。
表2不同单药组、试验组对大鼠血清ALT、AST、TC、TG水平的影响(n＝9，x2s)
注：与正常对照组比较：P＜0.05，P＜0.01；与模型对照组比较：*P＜0.05， **P＜0.01。
与正常对照组比较，模型对照组血清中ALT、AST活性明显增高(P ＜0.05)TC、TG增高不明显。与模型对照组比较，试验各组、单药各 组均使ALT活性显著降低P＜0.05)，试验各组降低ALT活性效果优于 单药各组。组合J4、J5活性显著性降低P＜0.05)。降低血清ALT、AST 的活性，说明药物对大鼠急性酒精性肝损伤有保护作用。各组对TC、 TG无明显影响。
对酒精性肝损伤大鼠肝匀浆MDA、GSH-PX活性、SOD含量的影 响:
酒精能引起小鼠肝脏MDA含量显著升高、引起GSH-PX酶、SOD 活性显著降低，而本发明组合物能显著降低MDA含量，能显著升高 GSH-PX酶、SOD活性。见表3。
表3不同单药组、试验组对大鼠肝匀浆MDA、GSH-PX活性、SOD含量的的影响(n＝9，x±s)
注：与正常对照组比较：P＜0.05，P＜0.01；与模型对照组比较：*P＜0.05，**P＜0.01
组合用药对比单独用药，均能明显缓解急性酒精性肝损伤。组合 用药对急性酒精性肝损伤有明显的保护作用，可减轻酒精对肝脏的脂 质过氧化损伤，降低血清转氨酶活性，改善肝脏的病理组织变化。其 作用机制可能是通过对抗氧化应激，减轻酒精对肝细胞的直接损害作 用，从而起到保护肝细胞，改善肝功能的作用。其中组合J4、J5效果 尤其显著。

Claims (8)

1.一种肝脏保健组合物，其特征在于：活性成分由姜黄素，壳寡糖，黑胡椒，维生素B1，维生素B2，维生素B3，维生素B6，维生素C，维生素E，肌醇原料组成。
2.根据权利要求1所述的肝脏保健组合物，其特征在于，由下述重量份的原料组成：姜黄素10-200份，壳寡糖10-300份，黑胡椒5-50份，维生素B1 1-10份，维生素B2 1-10份，维生素B3 1-10份，维生素B6 1-10份，维生素C 1-20份，维生素E 1-50份，肌醇1-20份。
3.根据权利要求1或2所述的肝脏保健组合物，其特征在于，所述姜黄素的来源包括姜黄。
4.根据权利要求1所述的肝脏保健组合物，其特征在于，所述壳寡糖酶法制备，聚合度范围2-20。
5.根据权利要求1所述肝脏保健组合物，其特征在于，所述组合物与其他辅料混合，剂型包括软胶囊剂、硬胶囊、片剂、颗粒剂、口服剂、饮料、果冻、糖果或软糖。
6.权利要求1-4任意一项所述肝脏保健组合物的制备方法，其特征在于，将所述原料按照比例进行物理混合处理，即得到所述肝脏保健组合物。
7.权利要求1-4任意一项所述肝脏保健组合物的应用，其特征在于，用于保健食品。
8.根据权利要求7所述的应用，所述保健食品包括功能性食品。
CN201810678769.7A 2018-06-27 2018-06-27 一种含姜黄素的肝脏保健组合物及其方法和应用 Pending CN108720018A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810678769.7A CN108720018A (zh) 2018-06-27 2018-06-27 一种含姜黄素的肝脏保健组合物及其方法和应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810678769.7A CN108720018A (zh) 2018-06-27 2018-06-27 一种含姜黄素的肝脏保健组合物及其方法和应用

Publications (1)

Publication Number Publication Date
CN108720018A true CN108720018A (zh) 2018-11-02

Family

ID=63931146

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810678769.7A Pending CN108720018A (zh) 2018-06-27 2018-06-27 一种含姜黄素的肝脏保健组合物及其方法和应用

Country Status (1)

Country Link
CN (1) CN108720018A (zh)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110742897A (zh) * 2019-12-04 2020-02-04 山东陆海蓝圣生物科技股份有限公司 一种壳寡糖与姜黄素的复合物及应用
CN111357910A (zh) * 2020-04-20 2020-07-03 江苏慧博生物科技有限公司 一种姜黄胡椒固体饮料及其制备方法
CN112155213A (zh) * 2020-09-30 2021-01-01 迪沙药业集团有限公司 一种解酒护肝的组合物及其制备方法

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1478532A (zh) * 2003-07-11 2004-03-03 诸暨永隆山生物科技工程有限公司 解酒护肝液产品及其生产方法
CA2732635A1 (en) * 2008-07-31 2010-02-04 Santosh Kumar Kar Curcumin nanoparticles and methods of producing the same
CN103535742A (zh) * 2013-09-27 2014-01-29 应博 解酒保肝组合物
CN104382893A (zh) * 2014-10-24 2015-03-04 青岛科技大学 一种ve、vc和姜黄素为主药成分的软胶囊
CN104489698A (zh) * 2014-12-02 2015-04-08 汤臣倍健股份有限公司 一种组合物、用途及保健品
CN105232588A (zh) * 2015-11-13 2016-01-13 青岛明月海藻集团有限公司 一种具有保护酒精性肝损伤作用的保健食品及制备方法
CN106344603A (zh) * 2016-08-05 2017-01-25 青岛壳寡糖生物科技有限公司 壳寡糖用于醒酒护肝的用途
CN106692189A (zh) * 2017-01-25 2017-05-24 中国科学院化学研究所 一种保护肝脏的组合物
CN107156849A (zh) * 2017-07-12 2017-09-15 广州若晖生物科技有限公司 一种含姜黄素的关节保健组合物及其应用

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1478532A (zh) * 2003-07-11 2004-03-03 诸暨永隆山生物科技工程有限公司 解酒护肝液产品及其生产方法
CA2732635A1 (en) * 2008-07-31 2010-02-04 Santosh Kumar Kar Curcumin nanoparticles and methods of producing the same
CN103535742A (zh) * 2013-09-27 2014-01-29 应博 解酒保肝组合物
CN104382893A (zh) * 2014-10-24 2015-03-04 青岛科技大学 一种ve、vc和姜黄素为主药成分的软胶囊
CN104489698A (zh) * 2014-12-02 2015-04-08 汤臣倍健股份有限公司 一种组合物、用途及保健品
CN105232588A (zh) * 2015-11-13 2016-01-13 青岛明月海藻集团有限公司 一种具有保护酒精性肝损伤作用的保健食品及制备方法
CN106344603A (zh) * 2016-08-05 2017-01-25 青岛壳寡糖生物科技有限公司 壳寡糖用于醒酒护肝的用途
CN106692189A (zh) * 2017-01-25 2017-05-24 中国科学院化学研究所 一种保护肝脏的组合物
CN107156849A (zh) * 2017-07-12 2017-09-15 广州若晖生物科技有限公司 一种含姜黄素的关节保健组合物及其应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
刘利萍等: ""姜黄素协同氨基葡萄糖对小鼠急性酒精性肝损伤的保护作用"", 《中国新药杂志》 *
孙涛等: "《国医年鉴（2017卷）》", 31 May 2017, 中医古籍出版社 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110742897A (zh) * 2019-12-04 2020-02-04 山东陆海蓝圣生物科技股份有限公司 一种壳寡糖与姜黄素的复合物及应用
CN111357910A (zh) * 2020-04-20 2020-07-03 江苏慧博生物科技有限公司 一种姜黄胡椒固体饮料及其制备方法
CN112155213A (zh) * 2020-09-30 2021-01-01 迪沙药业集团有限公司 一种解酒护肝的组合物及其制备方法

Similar Documents

Publication Publication Date Title
Mitra et al. Prospective multifunctional roles and pharmacological potential of dietary flavonoid narirutin
Kifayatullah et al. Evaluation of the acute and sub-acute toxicity of the ethanolic extract of Pericampylus glaucus (Lam.) Merr. in BALB/c mice
Mertens-Talcott et al. Pharmacokinetics of anthocyanins and antioxidant effects after the consumption of anthocyanin-rich acai juice and pulp (Euterpe oleracea Mart.) in human healthy volunteers
Thakur et al. Momordica balsamina: a medicinal and neutraceutical plant for health care management
Zarei et al. A quick overview on some aspects of endocrinological and therapeutic effects of Berberis vulgaris L.
US9694045B2 (en) Pharmaceutical composition for preventing or treating inflammatory diseases comprising trachelospermi caulis extract and paeonia suffruticosa andrews extract, and method for preparing the same
Gbadamosi et al. Nutritional composition of ten ethnobotanicals used for the treatment of anaemia in southwest Nigeria.
Khan et al. Phytochemical and pharmacological properties on Citrus limetta (Mosambi)
Olivier et al. Annickia affinis and A. chlorantha (Enantia chlorantha)–a review of two closely related medicinal plants from tropical Africa
Shahwar et al. Hypoglycemic Activity of Ruellia tuberosa Linn (Acanthaceae) in Normal and Alloxan-Induced Diabetic Rabbits: Hypoglycemic Activity of Ruellia tuberosa Linn
Zohrameena et al. Medicinal uses & pharmacological activity of Tamarindus indica
CN108720018A (zh) 一种含姜黄素的肝脏保健组合物及其方法和应用
Jimmy Coleus aromaticus Benth.: an update on its bioactive constituents and medicinal properties
WO2019017603A2 (ko) 마름 추출물 및 커큐민을 유효성분으로 함유하는 숙취 개선용 조성물
Rahiman et al. Oleuropein and oleic acid: A novel emerging dietary target for human chronic diseases
Ita et al. Acetaminophen induced hepatic toxicity: protective role of Ageratum conyzoides
Lim Opuntia ficus-indica
Kotue et al. Ethnobotanicals usages in the management of sickle cell disease (SDC) in some localities of Cameroon
El-Hadary Antioxidant and hypoglycemic activity of doum fruit (hyphaene thebaica. L) extracts on diabetic albino rats
Lim et al. Cydonia oblonga
Dubey et al. Sea buckthorn: A Potential Dietary supplement with multifaceted therapeutic activities
KR20180075763A (ko) 마치현 주정 추출물을 유효성분으로 함유하는 알콜성 간손상 예방, 개선 및 치료용 조성물
El-Sherif et al. Comparative Study for Group of Herbs VS. Glucophage Drug as Used for Obese Male Albino Rats
Sari et al. Overview of traditional use, phytochemical and pharmacological activities of cucumber (Cucumis sativus L.)
González-Stuart Multifaceted therapeutic value of roselle (Hibiscus sabdariffa L.–Malvaceae)

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20181102